Your browser doesn't support javascript.
loading
Azelastine nasal spray inhibiting sympathetic function on human nasal mucosa in patients with allergy rhinitis.
Cheng, L-H; Lee, J-C; Wu, P-C; Lin, Y-Y; Chu, Y-H; Wang, H-W.
Afiliación
  • Cheng LH; Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center.
  • Lee JC; Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center.
  • Wu PC; Department of Psychiatry, Far Eastern Memorial Hospital, New Taipei City, Taiwan, Republic of China.
  • Lin YY; Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center.
  • Chu YH; Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center.
  • Wang HW; Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center; Graduate Institute of Clinical Medicine and Department of Otolaryngology, Taipei Medical University-Shuang Ho Hospital.
Rhinology ; 57(4): 268-272, 2019 Aug 01.
Article en En | MEDLINE | ID: mdl-30887967
ABSTRACT

BACKGROUND:

Azelastine hydrochloride (azelastine) nasal spray is a histamine receptor-1 (H1) antagonist often used in treating allergic rhinitis to relieve its symptoms. However, the effects of azelastine to influence decongestion on human nasal mucosa in patients with allergic rhinitis are not yet fully explored and merit further exploration. The effects of azelastine on the vasocontractile responses generated by smooth muscles in the vascular structures of human nasal mucosa were investigated directly in vitro.

METHODS:

We examined the effectiveness of azelastine on isolated human nasal mucosa by testing 1) the effect on mucosa resting tension; 2) the effect on mucosal contraction caused by 10-6 M methoxamine as a sympathetic mimetic; 3) the effect of the drugs on electrically induced mucosal contractions.

RESULTS:

The results indicated that addition of methoxamine to the incubation medium caused the nasal mucosa to contract in a dose-dependent manner. Addition of azelastine at doses of 10â€"6 M or above elicited a significant dilation response to 10â€"6 M methoxamine-induced mucosal contraction. Azelastine could inhibit electrical field stimulation-induced spike mucosal contraction. Moreover, increase in concentration of azelastine had minimal effect on basal tension of nasal mucosa.

CONCLUSIONS:

The technique in our study is simple and reproducible. Azelastine could inhibit both EFS and methoxamine-induced nasal mucosal contractions in vitro. This study highlights that although azelastine nasal spray is often used in treating allergic rhinitis to improve symptoms, nasal obstruction may be not relieved immediately due to the anti-sympathetic effect of azelastine.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ftalazinas / Rinitis / Antiinflamatorios no Esteroideos / Rinitis Alérgica / Mucosa Nasal Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Rhinology Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ftalazinas / Rinitis / Antiinflamatorios no Esteroideos / Rinitis Alérgica / Mucosa Nasal Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Rhinology Año: 2019 Tipo del documento: Article